Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01949077|
Recruitment Status : Withdrawn
First Posted : September 24, 2013
Last Update Posted : November 8, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||January 2016|
Sustained virological response
Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
- Level (ng/mL) of serum chemokines. [ Time Frame: Baseline: <=6 months prior to start of treatment and Post-treatment: <=6-months after the last dose ]Compare levels of serum chemokines across Boceprevir responders (SVR) and non-responders for both Baseline (<=6-months pre-treatment) and Post-treatment (<=6-months post-treatment).
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01949077
|United States, North Carolina|
|University of North Carolina Liver Center|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||Michael W Fried, MD||University of North Carolina, Chapel Hill|